Related Experiment Videos
Serum soluble fas level as a prognostic factor in patients with gynecological malignancies
1Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan. konno@ob-gy.med.tohoku.ac.jp
Abstract:
The Fas-Fas ligand system is important in apoptosis mediated by CTLs and natural killer cells. The suppression of apoptosis contributes to carcinogenesis, as well as to a resistance to chemotherapy and radiotherapy. Circulating soluble Fas (sFas), which is generated by alternative mRNA splicing, can antagonize cell-surface Fas function. We investigated sFas levels in 64 patients with gynecological malignancies (28 cervical carcinomas, 18 endometrial carcinomas, and 18 ovarian carcinomas) and in 24 healthy female donors by using a Fas-specific ELISA. In each carcinoma group, serum sFas demonstrated a statistically significant elevation relative to levels in normal controls (P < 0.0001). Levels of serum sFas in patients with advanced cancer (FIGO stages III and IV) significantly exceeded those in patients with localized cancer (FIGO stages I and II) or those in normal control subjects (P < 0.0001). We divided the patients into two groups based on the level of serum sFas and examined the relationship between serum sFas levels and survival. No deaths occurred in the groups with cervical and endometrial cancer with a serum sFas level < 1.5 ng/ml. Survival rates in groups with cervical carcinoma, endometrial carcinoma, and ovarian carcinoma with a serum sFas level < 1.5 ng/ml exceeded those in groups with sFas levels of 21.5 ng/ml (P < 0.001, P = 0.128, and P = 0.012, respectively). Proportional hazard models demonstrated that serum sFas level was a statistically significant factor (P = 0.0196) for survival, as well as histological grade (P = 0.0168) in ovarian carcinoma.
Insights
Elevated soluble Fas (sFas) levels in patients with gynecological cancers indicate poorer survival outcomes. Lower sFas levels correlate with improved survival, suggesting sFas as a prognostic biomarker for these malignancies.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- The Fas-Fas ligand system regulates apoptosis, crucial for immune surveillance and tumor suppression.
- Dysregulation of apoptosis is linked to cancer development and resistance to therapies.
- Soluble Fas (sFas), a splice variant, can inhibit cell-surface Fas, potentially impacting cancer progression.
Purpose of the Study:
- To investigate serum soluble Fas (sFas) levels in patients with gynecological malignancies.
- To determine the correlation between sFas levels and cancer stage and patient survival.
- To evaluate sFas as a potential prognostic biomarker in cervical, endometrial, and ovarian cancers.
Main Methods:
- Serum samples were collected from 64 patients with gynecological cancers and 24 healthy controls.
- Fas-specific ELISA was employed to quantify serum sFas concentrations.
- Statistical analyses, including proportional hazard models, were used to assess relationships between sFas levels, cancer stage, and survival.
Main Results:
- Serum sFas levels were significantly elevated in all patient groups compared to healthy controls (P < 0.0001).
- Advanced cancer stages (FIGO III/IV) showed significantly higher sFas levels than localized stages (FIGO I/II) (P < 0.0001).
- Lower sFas levels (< 1.5 ng/ml) were associated with improved survival rates across cervical, endometrial, and ovarian carcinoma groups.
Conclusions:
- Elevated serum sFas is a common feature of gynecological malignancies.
- Serum sFas levels correlate with cancer stage and are a significant prognostic factor for patient survival.
- sFas represents a potential biomarker for predicting outcomes in gynecological cancer patients.